Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1

References

• World Health Organization. Number of deaths by region, Diarrhoeal diseases. World Health Organization Global Health Observatory. [Accessed March 9, 2020]. http://apps.who.int/gho/data/view.main.CM1002015REG6-CH3?lang=en.
   Google Scholar
• Global Burden of Disease Collaborative Network. Global burden of disease study 2017 (GBD 2017) results. [Accessed February 14, 2020]. http://ghdx.healthdata.org/gbd-results-tool.
   Google Scholar
• Tate JE, Burton AH, Boschi-Pinto C, Parashar UD. World health organization–coordinated global rotavirus surveillance network. Global, regional, and national estimates of rotavirus mortality in children <5 Years of Age, 2000-2013. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016;62(Suppl 2):S96–S105. doi:10.1093/cid/civ1013.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Rotavirus. centers for disease control and prevention. [Published September 25, 2019; accessed February 23, 2020]. https://www.cdc.gov/vaccines/pubs/pinkbook/rota.html.
   Google Scholar
• Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, Sur D, Breiman RF, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet Lond Engl. 2013;382(9888):209–22. doi:10.1016/S0140-6736(13)60844-2.
   PubMed Web of Science ®Google Scholar
• Liu J, Platts-Mills JA, Juma J, Kabir F, Nkeze J, Okoi C, Operario DJ, Uddin J, Ahmed S, Alonso PL, et al. Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study. Lancet Lond Engl. 2016;388(10051):1291–301. doi:10.1016/S0140-6736(16)31529-X.
   PubMed Web of Science ®Google Scholar
• ROTA Council at International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg school of public health. Rotavirus disease and immunization: the epidemiology and disease burden of rotavirus. [Published 2019; accessed March 9, 2020]. http://rotacouncil.org/wp-content/uploads/2019/05/ROTA-Brief3-Burden-SP-1.pdf.
   Google Scholar
• Kotloff KL. The Burden and Etiology of Diarrheal Illness in Developing Countries. Pediatr Clin North Am. 2017;64(4):799–814. doi:10.1016/j.pcl.2017.03.006.
   PubMed Web of Science ®Google Scholar
• Gavi Secretariat and Partners. Gavi- supported rotavirus vaccine profiles to support country decision making. [Published July 2019; accessed March 31, 2020]. https://www.gavi.org/sites/default/files/document/rotavirus-vaccine-profilespdf.pdf.
   Google Scholar
• Bhatnagar S, Bahl R, Sharma PK, Kumar GT, Saxena SK, Bhan MK. Zinc With Oral Rehydration Therapy Reduces Stool Output and Duration of Diarrhea in Hospitalized Children: A Randomized Controlled Trial. J Pediatr Gastroenterol Nutr. 2004;38(1):34–40. doi:10.1097/00005176-200401000-00010.
   PubMed Web of Science ®Google Scholar
• Santosham M, Chandran A, Fitzwater S, Fischer-Walker C, Baqui AH, Black R. Progress and barriers for the control of diarrhoeal disease. Lancet. 2010;376(9734):63–67. doi:10.1016/S0140-6736(10)60356-X.
   PubMed Web of Science ®Google Scholar
• Yen C, Healy K, Tate JE, Parashar UD, Bines J, Neuzil K, Santosham M, Steele AD. Rotavirus vaccination and intussusception - Science, surveillance, and safety: A review of evidence and recommendations for future research priorities in low and middle income countries. Hum Vaccines Immunother. 2016;12(10):2580–89. doi:10.1080/21645515.2016.1197452.
   PubMed Web of Science ®Google Scholar
• Cook SM, Glass RI, LeBaron CW, Ho MS. Global seasonality of rotavirus infections. Bull World Health Organ. 1990;68:171–77.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Rotavirus. [Published September 5, 2018; accessed January 29, 2020]. https://www.who.int/immunization/monitoring_surveillance/burden/vpd/WHO_SurveillanceVaccinePreventable_19_Rotavirus_R2.pdf?ua=1.
   Google Scholar
• World Health Organization. 2009. Rotavirus Vaccines: an Update. World Health Organization. 533–40.
   Google Scholar
• VIEW-hub. [Accessed February 3, 2020]. https://view-hub.org/viz/?YXBwaWQ9MSZpbmRpY2F0b3JpZD02MCZvdmVybGF5aWQ9NA==.
   Google Scholar
• Marwick C. Rotavirus Vaccine a Boon to Children. JAMA. 1998;279(7):489–90. doi:10.1001/jama.279.7.489.
   PubMed Web of Science ®Google Scholar
• Schwartz JL. The First Rotavirus Vaccine and the Politics of Acceptable Risk: first Rotavirus Vaccine and Politics of Acceptable Risk. Milbank Q. 2012;90(2):278–310. doi:10.1111/j.1468-0009.2012.00664.x.
   PubMed Web of Science ®Google Scholar
• Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Innate Immunity. Mol Biol Cell. 4th ed. 2002 [Published; Accessed January 29]. https://www.ncbi.nlm.nih.gov/books/NBK26846/
   Web of Science ®Google Scholar
• Desselberger U, Huppertz H-I. Immune Responses to Rotavirus Infection and Vaccination and Associated Correlates of Protection. J Infect Dis. 2011;203(2):188–95. doi:10.1093/infdis/jiq031.
   PubMed Web of Science ®Google Scholar
• Ogden KM, Tan Y, Akopov A, Stewart LS, McHenry R, Fonnesbeck CJ, Bhinnata P, Carter MH, Fedorova NB, Halpin RA, et al. Multiple Introductions and Antigenic Mismatch with Vaccines May Contribute to Increased Predominance of G12P[8] Rotaviruses in the United States. López S, ed. J Virol. 2018;93(1):e01476–18. /jvi/93/1/JVI.01476-18.atom. doi:10.1128/JVI.01476-18.
   PubMed Web of Science ®Google Scholar
• Lappalainen S, Pastor AR, Tamminen K, López-Guerrero V, Esquivel-Guadarrama F, Palomares LA, Vesikari T, Blazevic V. Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo. Hum Vaccines Immunother. 2014;10(7):2039–47. doi:10.4161/hv.28858.
   PubMed Web of Science ®Google Scholar
• Angel J, Steele AD, Franco MA. Correlates of protection for rotavirus vaccines: possible alternative trial endpoints, opportunities, and challenges. Hum Vaccines Immunother. 2014;10(12):3659–71. doi:10.4161/hv.34361.
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354(1):11–22. doi:10.1056/NEJMoa052434.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, et al. Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus Vaccine. N Engl J Med. 2006;354(1):23–33. doi:10.1056/NEJMoa052664.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Rotavirus vaccines. WHO position paper – january 2013. Releve Epidemiol Hebd. 2013;88(5):49–64.
   PubMedGoogle Scholar
• Patel MM, Steele D, Gentsch JR, Wecker J, Glass RI, Parashar UD. Real-world Impact of Rotavirus Vaccination. Pediatr Infect Dis J. 2011;30(1):S1. doi:10.1097/INF.0b013e3181fefa1f.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Vaccine Adverse Event Reporting System (VAERS) | monitoring | ensuring Safety | vaccine Safety | CDC. [Published December 11, 2019; accessed February 3, 2020]. https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vaers/index.html.
   Google Scholar
• Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S, Goyal N, Kawade A, Kang G, Rathore SS, et al. Efficacy of a Monovalent Human-Bovine (116E) Rotavirus Vaccine in Indian Infants: A Randomised Double Blind Placebo Controlled Trial. Lancet Lond Engl. 2014;383(9935):2136–43. doi:10.1016/S0140-6736(13)62630-6.
   PubMed Web of Science ®Google Scholar
• Kulkarni PS, Desai S, Tewari T, Kawade A, Goyal N, Garg BS, Kumar D, Kanungo S, Kamat V, Kang G, et al. A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Vaccine. 2017;35(45):6228–37. doi:10.1016/j.vaccine.2017.09.014.
   PubMed Web of Science ®Google Scholar
• Weintraub ES, Baggs J, Duffy J, Vellozzi C, Belongia EA, Irving S, Klein NP, Glanz JM, Jacobsen SJ, Naleway A, et al. Risk of Intussusception after Monovalent Rotavirus Vaccination. N Engl J Med. 2014;370(6):513–19. doi:10.1056/NEJMoa1311738.
   PubMed Web of Science ®Google Scholar
• Patel MM, López-Collada VR, Bulhões MM, De Oliveira LH, Márquez AB, Flannery B, Esparza-Aguilar M, Montenegro Renoiner EI, Luna-Cruz ME, Sato HK, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med. 2011;364(24):2283–92. doi:10.1056/NEJMoa1012952.
   PubMed Web of Science ®Google Scholar
• Velázquez FR, Colindres RE, Grajales C, Hernández MT, Mercadillo MG, Torres FJ, Cervantes-Apolinar M, DeAntonio-Suarez R, Ortega-Barria E, Blum M, et al. Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. Pediatr Infect Dis J. 2012;31(7):736–44. doi:10.1097/INF.0b013e318253add3.
   PubMed Web of Science ®Google Scholar
• Stowe J, Andrews N, Ladhani S, Miller E. The risk of intussusception following monovalent rotavirus vaccination in England: A self-controlled case-series evaluation. Vaccine. 2016;34(32):3684–89. doi:10.1016/j.vaccine.2016.04.050.
   PubMed Web of Science ®Google Scholar
• Haber P, Patel M, Pan Y, Baggs J, Haber M, Museru O, Yue X, Lewis P, DeStefano F, Parashar UD, et al. Intussusception after rotavirus vaccines reported to US VAERS, 2006-2012. Pediatrics. 2013;131(6):1042–49. doi:10.1542/peds.2012-2554.
   PubMed Web of Science ®Google Scholar
• Haber P, Parashar UD, Haber M, DeStefano F. Intussusception after monovalent rotavirus vaccine-United States, Vaccine Adverse Event Reporting System (VAERS), 2008-2014. Vaccine. 2015;33(38):4873–77. doi:10.1016/j.vaccine.2015.07.054.
   PubMed Web of Science ®Google Scholar
• Carlin JB, Macartney KK, Lee KJ, Quinn HE, Buttery J, Lopert R, Bines J, McIntyre PB. Intussusception risk and disease prevention associated with rotavirus vaccines in Australia’s National Immunization Program. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;57(10):1427–34. doi:10.1093/cid/cit520.
   PubMed Web of Science ®Google Scholar
• Tate JE, Mwenda JM, Lopman Armah BAG, Jani B, Omore R, Ademe A, Mujuru H, Mpabalwani E, Ngwira B, Cortese MM, et al. Evaluation of Intussusception after Monovalent Rotavirus Vaccination in Africa. N Engl J Med. 2018;378(16):1521–28. doi:10.1056/NEJMoa1713909.
   PubMed Web of Science ®Google Scholar
• Mayo Clinic. Intussusception. [Published 2020]. https://www.mayoclinic.org/diseases-conditions/intussusception/symptoms-causes/syc-20351452.
   Google Scholar
• World Health Organization. Rotavirus vaccine safety update. World Health Organization. [Accessed February 3, 2020]. http://www.who.int/vaccine_safety/committee/topics/rotavirus/rotarix_and_rotateq/dec_2017/en/.
   Google Scholar
• Early Rollout of ROTAVAC® India Network. Assessment of risk of intussusception after pilot rollout of rotavirus vaccine in the Indian public health system. Vaccine. 2020;38(33):5241–48. doi:10.1016/j.vaccine.2020.05.093.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Advisory Committee on Vaccine Safety, 4–5 December 2019. Wkly Epidemiol Rec. 2020;95(4):25–36.
   Google Scholar
• Riveros X Overview of characteristics of RV vaccines licensed and/or in clinical evaluation phase. Presented at the: Rotavirus scoping meeting. October 2, 2017. [Accessed February 13, 2020] https://www.who.int/immunization/research/meetings_workshops/3_RV_vaccines_RX_oct17.pdf.
   Google Scholar
• Dang DA, Nguyen VT, Vu DT, Anh NTH, Mao ND, Wang Y, Jiang B, Hien ND, Luan LT. A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children. Vaccine. 2012;30(Suppl 1):A114–121. doi:10.1016/j.vaccine.2011.07.118.
   PubMed Web of Science ®Google Scholar
• World Health Organization. About WHO prequalification of vaccines. WHO. [Accessed February 24, 2020]. http://www.who.int/medicines/regulation/prequalification/prequal-vaccines/about/en/.
   Google Scholar
• ClinicalTrials.gov. Identifier NCT03703336, Phase III study of liquid formulation of ROTAVIN. NIH U.S. National Library of Medicine. [Published January 25, 2019; accessed March 31, 2020]. https://clinicaltrials.gov/ct2/show/NCT03703336.
   Google Scholar
• ROTA Council at International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg school of public health. Current and Upcoming Rotavirus Vaccines. ROTA Council:7. [Accessed February 24, 2020]. http://rotacouncil.org/wp-content/uploads/2019/05/ROTA-Brief2-ProductLandscape-SP-1-3.pdf.
   Google Scholar
• Deen J, Lopez AL, Kanungo S, Wang X-Y, Anh DD, Tapia M, Grais RF. Improving rotavirus vaccine coverage: can newer-generation and locally produced vaccines help? Hum Vaccines Immunother. 2018;14(2):495–99. doi:10.1080/21645515.2017.1403705.
   PubMed Web of Science ®Google Scholar
• Hansen LJJ, Daoussi R, Vervaet C, Remon J-P, De Beer TRM. Freeze-drying of live virus vaccines: A review. Vaccine. 2015;33(42):5507–19. doi:10.1016/j.vaccine.2015.08.085.
   PubMed Web of Science ®Google Scholar
• Naik SP, Zade JK, Sabale RN, Pisal SS, Menon R, Bankar SG, Gairola S, Dhere RM. Stability of heat stable, live attenuated Rotavirus vaccine (ROTASIIL®). Vaccine. 2017;35(22):2962–69. doi:10.1016/j.vaccine.2017.04.025.
   PubMed Web of Science ®Google Scholar
• World Health Organization. What is VVM and how does it work? [Accessed February 24, 2020]. https://www.who.int/immunization_standards/vaccine_quality/What%20is%20VVM%20and%20how%20does%20it%20work.pdf?ua=1.
   Google Scholar
• Serum Institute of India Pvt. Ltd. Rotavirus vaccine live attenuated, oral (Freeze-Dried). Serum Institute of India Pvt. Ltd. [Accessed March 31, 2020]. https://www.seruminstitute.com/product_viral_rotasiil.php.
   Google Scholar
• Kawade A, Babji S, Kamath V, Raut A, Kumar CM, Kundu R, Venkatramanan P, Lalwani SK, Bavdekar A, Juvekar S, et al. Immunogenicity and lot-to-lot consistency of a ready to use liquid bovine-human reassortant pentavalent rotavirus vaccine (ROTASIIL - Liquid) in Indian infants. Vaccine. 2019;37(19):2554–60. doi:10.1016/j.vaccine.2019.03.067.
   PubMed Web of Science ®Google Scholar
• Anil K, Desai S, Bhamare C, Dharmadhikari A, Madhusudhan RL, Patel J, Kulkarni PS. Safety and tolerability of a liquid bovine rotavirus pentavalent vaccine (LBRV-PV) in adults. Vaccine. 2018;36(12):1542–44. doi:10.1016/j.vaccine.2018.02.024.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Identifier NCT01375907, Safety study of a rotavirus vaccine (Rotavin-M1) among healthy adults. NIH U.S. National Library of Medicine. [Published July 4, 2016; accessed March 31, 2020]. https://clinicaltrials.gov/ct2/show/NCT01375907.
   Google Scholar
• ClinicalTrials.gov. Identifier NCT01377571, A dose-escalating study to evaluate the immunogenicity and safety of Rotavin-M1 vaccine in healthy infants. NIH U.S. National Library of Medicine. [Published July 4, 2016; accessed March 31, 2020]. https://clinicaltrials.gov/ct2/show/NCT01377571.
   Google Scholar
• ClinicalTrials.gov. Identifier NCT01502969, safety and immunogenicity assessment of Rotavin-M1 in vietnamese children. NIH U.S. National Library of Medicine. [published January 2, 2012; accessed March 31, 2020]. https://clinicaltrials.gov/ct2/show/NCT01502969.
   Google Scholar
• Bhandari N, Sharma P, Glass RI, Ray P, Greenberg H, Taneja S, Saksena M, Rao CD, Gentsch JR, Parashar U, et al. Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial. Vaccine. 2006;24(31–32):5817–23. doi:10.1016/j.vaccine.2006.05.001.
   PubMed Web of Science ®Google Scholar
• Bhandari N, Sharma P, Taneja S, Kumar T, Rongsen‐Chandola T, Appaiahgari M, Mishra A, Singh S, Vrati S. A Dose-Escalation Safety and Immunogenicity Study of Live Attenuated Oral Rotavirus Vaccine 116E in Infants: A Randomized, Double-Blind, Placebo‐Controlled Trial. J Infect Dis. 2009;200(3):421–29. doi:10.1086/600104.
   PubMed Web of Science ®Google Scholar
• Appaiahgari MB, Glass R, Singh S, Taneja S, Rongsen-Chandola T, Bhandari N, Mishra S, Vrati S. Transplacental rotavirus IgG interferes with immune response to live oral rotavirus vaccine ORV-116E in Indian infants. Vaccine. 2014;32(6):651–56. doi:10.1016/j.vaccine.2013.12.017.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Identifier NCT03602053, Study of BBIL’s ROTAVAC® and ROTAVAC 5CM Vaccines in Zambia. NIH U.S. National Library of Medicine. [Published February 20, 2020; accessed March 31, 2020]. https://clinicaltrials.gov/ct2/show/NCT03602053.
   Google Scholar
• ClinicalTrials.gov. Identifier NCT01305109, A Phase III clinical trial to evaluate the protective efficacy of three doses of oral rotavirus vaccine (ORV) 116E. NIH U.S. National Library of Medicine. Ppublished June 12, 2012; accessed March 31, 2020]. https://clinicaltrials.gov/ct2/show/NCT01305109.
   Google Scholar
• Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S, Goyal N, Kawade A, Kang G, Rathore SS, et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life. Vaccine. 2014;32:A110–A116. doi:10.1016/j.vaccine.2014.04.079.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Evaluate immunogenicity, safety, and reactogenicity of Rotavac® in healthy infants aged between 6-8 weeks in Vietnam - full text view - ClinicalTrials.gov. NIH U.S. National Library of Medicine. [Published March 25, 2019; accessed March 31, 2020]. https://clinicaltrials.gov/ct2/show/NCT03367559.
   Google Scholar
• Chandola TR, Taneja S, Goyal N, Antony K, Bhatia K, More D, Bhandari N, Cho I, Mohan K, Prasad S, et al. ROTAVAC® ROTAVAC ® does not interfere with the immune response to childhood vaccines in Indian infants: A randomized placebo controlled trial. Heliyon. 2017;3(5):e00302. doi:10.1016/j.heliyon.2017.e00302.
   PubMed Web of Science ®Google Scholar
• Praharaj I, Platts-Mills JA, Taneja S, Antony K, Yuhas K, Flores J, Cho I, Bhandari N, Revathy R, Bavdekar A, et al. Diarrheal Etiology and Impact of Coinfections on Rotavirus Vaccine Efficacy Estimates in a Clinical Trial of a Monovalent Human–Bovine (116E) Oral Rotavirus Vaccine, Rotavac, India. Clin Infect Dis. 2019;69(2):243–50. doi:10.1093/cid/ciy896.
   PubMed Web of Science ®Google Scholar
• Ella R, Bobba R, Muralidhar S, Babji S, Vadrevu KM, Bhan MK, Phase A. 4, multicentre, randomized, single-blind clinical trial to evaluate the immunogenicity of the live, attenuated, oral rotavirus vaccine (116E), ROTAVAC®, administered simultaneously with or without the buffering agent in healthy infants in India. Hum Vaccines Immunother. 2018;14(7):1791–99. doi:10.1080/21645515.2018.1450709.
   PubMed Web of Science ®Google Scholar
• Ella R, Babji S, Ciarlet M, Blackwelder WC, Vadrevu KM. A randomized, open-labelled, non-inferiority phase 4 clinical trial to evaluate the immunogenicity and safety of the live, attenuated, oral rotavirus vaccine, ROTAVAC® in comparison with a licensed rotavirus vaccine in healthy infants. Vaccine. 2019;37(31):4407–13. doi:10.1016/j.vaccine.2019.05.069.
   PubMed Web of Science ®Google Scholar
• Zade JK, Kulkarni PS, Desai SA, Sabale RN, Naik SP, Dhere RM. Bovine rotavirus pentavalent vaccine development in India. Vaccine. 2014;32(Suppl 1):A124–128. doi:10.1016/j.vaccine.2014.03.003.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Identifier NCT03474055, study on liquid bovine rotavirus pentavalent vaccine (LBRV-PV) to evaluate lot-to-lot consistency and to compare non-inferiority with ROTASIIL (Lyophilized BRV-PV) in healthy infants in India. NIH U.S. National Library of Medicine. [Published September 10, 2018; accessed March 31, 2020]. https://clinicaltrials.gov/ct2/show/NCT03474055.
   Google Scholar
• ClinicalTrials.gov. Identifier NCT02133690, a clinical trial to study the effect and safety of rotavirus vaccine against severe rotavirus gastroenteritis in healthy Indian infants. NIH U.S. National Library of Medicine. [Published September 10, 2018; accessed March 31, 2020]. https://clinicaltrials.gov/ct2/show/NCT02133690.
   Google Scholar
• ClinicalTrials.gov. Identifier NCT02145000, efficacy and safety of a pentavalent rotavirus vaccine (BRV-PV) against severe rotavirus gastroenteritis in Niger. NIH U.S. National Library of Medicine. [Published August 14, 2019; accessed March 31, 2020]. https://clinicaltrials.gov/ct2/show/NCT02145000.
   Google Scholar
• Isanaka S, Guindo O, Langendorf C, Matar Seck A, Plikaytis BD, Sayinzoga-Makombe N, McNeal MM, Meyer N, Adehossi E, Djibo A, et al. Efficacy of a Low-Cost, Heat-Stable Oral Rotavirus Vaccine in Niger. N Engl J Med. 2017;376(12):1121–30. doi:10.1056/NEJMoa1609462.
   PubMed Web of Science ®Google Scholar
• Coldiron ME, Guindo O, Makarimi R, Soumana I, Matar Seck A, Garba S, Macher E, Isanaka S, Grais RF. Safety of a heat-stable rotavirus vaccine among children in Niger: data from a phase 3, randomized, double-blind, placebo-controlled trial. Vaccine. 2018;36(25):3674–80. doi:10.1016/j.vaccine.2018.05.023.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Identifier NCT02584816, Phase III study on rotavirus vaccine to evaluate lot-to-lot consistency and interference with routine UIP immunization. NIH U.S. National Library of Medicine. [Published September 11, 2018; accessed March 31, 2020]. https://clinicaltrials.gov/ct2/show/NCT02584816.
   Google Scholar
• Desai S, Rathi N, Kawade A, Venkatramanan P, Kundu R, Lalwani SK, Dubey AP, Venkateswara Rao J, Narayanappa D, Ghildiyal R, et al. Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL® with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine. Vaccine. 2018;36(37):5519–23. doi:10.1016/j.vaccine.2018.07.064.
   PubMed Web of Science ®Google Scholar
• Le LT, Nguyen TV, Nguyen PM, Huong NT, Huong NT, Huong NTM, Hanh TB, Ha DN, Anh DD, Gentsch JR, et al. Development and characterization of candidate rotavirus vaccine strains derived from children with diarrhoea in Vietnam. Vaccine. 2009;27:F130–F138. doi:10.1016/j.vaccine.2009.08.086.
   PubMed Web of Science ®Google Scholar
• Almalki SSR. Circulating rotavirus G and P strains post rotavirus vaccination in Eastern Mediterranean Region. Saudi Med J. 2018;39(8):755–56. doi:10.15537/smj.2018.6.21394.
   PubMed Web of Science ®Google Scholar
• Dóró R, László B, Martella V, Leshem E, Gentsch J, Parashar U, Bányai K. Review of global rotavirus strain prevalence data from six years post vaccine licensure surveillance: is there evidence of strain selection from vaccine pressure? Infect Genet Evol. 2014;28:446–61. doi:10.1016/j.meegid.2014.08.017.
   PubMed Web of Science ®Google Scholar
• Steele AD, Neuzil KM, Cunliffe NA, Madhi SA, Bos P, Ngwira B, Witte D, Todd S, Louw C, Kirsten M, et al. Human rotavirus vaccine RotarixTM provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infect Dis. 2012;12:213. doi:10.1186/1471-2334-12-213.
   PubMed Web of Science ®Google Scholar
• Payne DC, Boom JA, Staat MA, Edwards KM, Szilagyi PG, Klein EJ, Selvarangan R, Azimi PH, Harrison C, Moffatt M, et al. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;57(1):13–20. doi:10.1093/cid/cit164.
   PubMed Web of Science ®Google Scholar
• Soares-Weiser K Rotavirus Vaccines Schedules: A systematic review of safety and efficacy from randomized controlled trials and observational studies of childhood schedules using RV1 and RV5 vaccines:140.
   Google Scholar
• Pecenka C, Debellut F, Bar-Zeev N, Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S, Goyal N. Re-evaluating the cost and cost-effectiveness of rotavirus vaccination in Bangladesh, Ghana, and Malawi: A comparison of three rotavirus vaccines. Vaccine. 2018;36(49):7472–78. doi:10.1016/j.vaccine.2018.10.068.
   PubMed Web of Science ®Google Scholar
• Debellut F, Jaber S, Bouzya Y, Sabbah J, Barham M, Abu-Awwad F, Hjaija D, Ramlawi A, Pecenka C, Clark A, et al. Introduction of rotavirus vaccination in Palestine: an evaluation of the costs, impact, and cost-effectiveness of ROTARIX and ROTAVAC. PLoS ONE. 2020;15(2):2. doi:10.1371/journal.pone.0228506.
   Web of Science ®Google Scholar
• Pecenka C, Debellut F, Bar-Zeev N, Anwari P, Nonvignon J, Clark A. Cost-effectiveness analysis for rotavirus vaccine decision-making: how can we best inform evolving and complex choices in vaccine product selection? Vaccine. 2020;38(6):1277–79. doi:10.1016/j.vaccine.2019.12.014.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO programmatic guidance note use of more than one rotavirus vaccine product to complete the vaccination series. [Accessed February 25, 2020]. https://www.who.int/immunization/diseases/rotavirus/Rota_mixed_schedules_interchangeability.pdf?ua=1.
   Google Scholar
• Libster R, McNeal M, Walter EB, Shane AL, Winokur P, Cress G, Berry AA, Kotloff KL, Sarpong K, Turley CB, et al. Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules. Pediatrics. 2016;137(2):e20152603. doi:10.1542/peds.2015-2603.
   PubMed Web of Science ®Google Scholar
• Payne DC, Sulemana I, Parashar UD. Evaluation of effectiveness of mixed rotavirus vaccine course for rotavirus gastroenteritis. JAMA Pediatr. 2016;170(7):708–10. doi:10.1001/jamapediatrics.2016.0014.
   PubMed Web of Science ®Google Scholar
• Kanungo S, Datta S Rotavirus vaccine interchangeability trial begins enrolling participants in Kolkata, India. [accessed March 22, 2020]. http://www.niced.org.in/news/documents/2019/RVICS-trail-23Mar2019.pdf.
   Google Scholar
• Bharat Biotech. Bharat biotech launches ROTAVAC 5D® - Lowest dose volume rotavirus vaccine in the world. [accessed April 3, 2020]. https://www.bharatbiotech.com/images/press/Bharat-biotech-launches-ROTAVAC5D-lowest-dose-volume-rotavirus-vaccine-in-the-world.pdf.
   Google Scholar
• UNICEF. Rotavirus vaccine: supply and demand update. [published Nov 2018; accessed March 9, 2020]. https://www.unicef.org/supply/files/RV_Supply_Update.pdf.
   Google Scholar
• World Health Organization. WHO prequalified vaccines: rotasiil. WHO prequalified vaccines. [published Feb 25, 2020; accessed Feb 24, 2020]. https://extranet.who.int/gavi/PQ_Web/PreviewVaccine.aspx?nav=0&ID=323.
   Google Scholar
• World Health Organization. WHO prequalified vaccines: rotavac. WHO Prequalified Vaccines. [published Feb 25, 2020; accessed Feb 24, 2020]. https://extranet.who.int/gavi/PQ_Web/PreviewVaccine.aspx?nav=0&ID=314.
   Google Scholar
• Bharat Biotech. ROTAVAC multi dose product insert. [published March 2018; accessed April 5, 2020]. https://www.bharatbiotech.com/images/rotavac/Rotavac-multi-dose-package-Insert.pdf.
   Google Scholar